This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit August 05, 2014
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  



Introducing the Transplantation and Immunology Research Network
Last week, AST President Dr. Dan Salomon announced the official launch of the AST's Transplantation and Immunology Network (TIRN). In addition to supporting transplantation and immunology research, TIRN strives to create unique opportunities for collaboration between researchers and other transplantation and immunology professionals. It includes industry leaders in Pharma and biotech, private organizations, and academic institutions that support transplantation research and are committed to nurturing the next generation of investigators, in addition to the general public. Learn more about TIRN at
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Register early to receive a discounted rate!
ESOT + AST Joint Meeting
Personalized Transplantation: From New Diagnostics to New Therapeutics
Oct. 17-19, 2014
Madrid, Spain

Register by September 7 and save!

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Save the Date for the Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies

February 5-7, 2015
Sheraton Wild Horse Pass – Chandler, AZ

Make plans to attend this high-energy, intimate meeting featuring sessions on:

  • A Critical Review of Cell Therapies
  • Whatever Happened to Gene Therapy?
  • Organ Repair and Regeneration, and Organ Generation
  • Drug Development and Rediscovering Pathways
  • In vitro, In vivo, and In silico: Are We Done with Animal Models?

Website and call for basic, clinical and translational abstracts coming soon!

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.


Somatostatin therapy protects porcine livers in small-for-size liver transplantation
American Journal of Transplantation (log in required)
Small-for-size (SFS) injury occurs in partial liver transplantation due to several factors, including excessive portal inflow and insufficient intragraft responses. The authors aimed to determine the role somatostatin plays in reducing portal hyperperfusion and preventing the cascade of deleterious events produced in small grafts.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
Transplantation Research
Cardiac transplantation remains a definitive treatment option for patients with end-stage heart disease. Survival rates have improved dramatically. Nonetheless, progress in immunosuppression has been slower, partly because the heart is a fundamental organ and acute allograft rejection can include hemodynamic compromise, irreversible graft injury, and death. Furthermore, the immunosuppressive therapy used to prevent rejection increases the risk of infection, which continues to be a leading cause of death in the first year after cardiac transplantation. The purpose of this study was to test the efficacy and safety of daclizumab (DZM) versus anti-thymocyte globulin (ATG) as a component of induction therapy in heart transplant recipients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE

Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation
Clinical Transplantation (log in required)
The efficacy and safety of everolimus (EVR) in simultaneous pancreas and kidney transplantation (SPKT) is unclear. The authors retrospectively evaluated 25 consecutive SPKT recipients at our center from November 2011 to March 2013. All patients received dual induction (Thymoglobulin/basiliximab) and low-dose tacrolimus plus corticosteroids. Nine patients who received EVR were compared with 14 patients who received enteric-coated mycophenolate sodium (EC-MPS); two patients who received sirolimus were excluded from the analysis. With a median follow-up of 14 months, the pancreas graft survival rate was 100 percent in both groups, and the kidney graft survival rate was 100 percent and 93 percent in EVR and EC-MPS patients, respectively.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): A randomized trial
The Lancet (log in required)
Calcineurin inhibitors (CNIs) reduce short-term kidney transplant failure, but might contribute to transplant failure in the long-term. The role of alemtuzumab (a potent lymphocyte-depleting antibody) as an induction treatment followed by an early reduction in CNI and mycophenolate exposure and steroid avoidance, after kidney transplantation is uncertain. Researchers aimed to assess the efficacy and safety of alemtuzumab-based induction treatment compared with basiliximab-based induction treatment in patients receiving kidney transplants.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

The policy of placing older donors into older recipients: Is it worth the risk?
Clinical Transplantation (log in required)
To expand the donor pool, older donors (±50 yr) are frequently used in older recipients (±60 yr). Older recipients and those receiving older donor hearts have independently displayed decreased post-transplant survival. However, outcomes in older patients receiving older donor hearts are contentious.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Missed last week's issue? See which articles your colleagues read most.

    MRSA and VRE colonization in solid organ transplantation: A meta-analysis of published studies (American Journal of Transplantation)
Chronic hepatitis E in solid-organ transplantation: The key implications of immunosuppressants (Current Opinion in Infectious Diseases)
Morbidity and mortality of live lung donation: Results from the RELIVE Study
(American Journal of Transplantation)

Don't be left behind. Click here to see what else you missed.

AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news

This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
July 25, 2014
July 18, 2014
July 11, 2014
July 4, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063